$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Small extracellular vesicles (sEVs) are nanosized (~30-200 nm in diameter) cell-derived particles enveloped by a phospholipid bilayer membrane, which is inherited from their cell of origin and that robustly protects their molecular cargos1,2. It is well accepted that virtually all cells produce and release sEVs into the intercellular compartment, which can in turn be detected in most biofluids (i.e., blood, urine, saliva, etc)2,3,4. Recent studies have demonstrated that the stably encapsulated molecular cargos (i.e., DNA, RNA, proteins, lipids, etc)5,6,7 of sEVs, once in contact or delivered to recipient cells mediate intercellular communication8. Current research efforts have been focused on improving the isolation of cell-specific sEVs from diverse biofluids, to precisely identify and monitor these molecular cargos9,10. Considering that sEVs contain small non-coding RNAs and particularly microRNAs (miRNAs), which retain their regulatory function upon cellular delivery, many studies have been focused on evaluating the utility of miRNAs as biomarkers that can reveal the condition of their cell of origin11,12,13.
MicroRNAs (miRNAs) represent a large class (~2,000 known in humans) of small non-coding RNAs with sizes ranging between 19 and 25 nucleotides (nt), which bind to imperfect complementary sites in the 3' untranslated regions of their mRNA targets and direct their degradation and/or post-transcriptional repression14,15. Functionally, miRNAs have been described to control many biological processes, and the deregulation of their expression has been associated with alterations in molecular, biochemical, and physiological processes that contribute to the initiation and development of diseases, including cancer16,17,18. Importantly, studies have shown that diseased cells and particularly cancer cells, not only differentially express miRNAs in comparison to normal cells18, but that their packaging into sEVs also differs19,20.
While several studies focus on establishing the molecular processes and pathways that direct the packaging of sEVs in normal and diseased cells19,21,22, biomarker studies are currently focused on identifying distinguishable small non-coding RNA and/or miRNA signatures that are packaged and secreted by specific diseased/cancer cells via sEVs. The targeted isolation of diseased cell-specific sEVs from diverse human biofluids and the evaluation of their multi-omic molecular cargos may thus enable the development of diagnostic and prognostic assays for non-invasive detection of diverse human diseases and cancers23,24,25,26. Although sEV-miRNAs are the most studied non-coding transcripts, other small non-coding RNA species (i.e., miRNA isoforms (isomiRs), piwiRNAs, transfer RNA fragment (tRFs), rRNAs, orphan non-coding RNAs (oncRNAs)…) are also being evaluated for their potential usefulness as circulating sEV-biomarkers, with specific emphasis on the detection of different cancers27,28,29,30,31,32.
Advantageously, next-generation sequencing (NGS) analysis of small non-coding RNA transcripts (including miRNAs), following their barcoding and cDNA library preparation, is ideal for exploration of known and/or unknown small non-coding RNA species contained in circulating sEVs, which may be associated with diseases27. Indeed, sEV small-RNA NGS provides a high-throughput approach for the discovery of cell-specific small non-coding RNA transcripts that would otherwise remain unknown, if globally evaluated with target-specific technologies (i.e., multiplex PCR, microarrays, customized panels, etc.)32,33,34. Considering that we previously optimized an ultra-sensitive, highly reproducible cDNA library preparation protocol, which we developed for the analysis of highly degraded and low-concentration formalin-fixed paraffin-embedded (FFPE) RNAs35,36, we sought to adapt it for the analysis of small non-coding RNAs and miRNAs encapsulated within sEVs37,38,39,40.
With the discontinuation of the Illumina HiSeq2500 instrument, which provided us with years of high-quality single-end dual index miRNA analysis of sEV cargos37,40, we sought to explore the reproducibility and sensitivity of our protocol when adapted to updated sequencing instruments using now paired-end dual index chemistry. With the intent to retain the multiplexing capabilities of the original protocol, we maintained the existing 16 barcodes for the preparation of small-RNA cDNA transcripts before integrating them within paired-end dual index chemistry. Using only a pair of i5 and i7 barcodes, we enable the preparation of a robust laboratory-based cDNA library where simultaneous processing and analysis of up to 16 individual samples improve analytical reproducibility of low-input sEV RNA. Thus, we present the biochemical processes, the updated barcodes, PCR and size marker primers, and isolation steps necessary to generate highly reproducible cDNA libraries using ultra-low amounts of miRNAs isolated from human plasma sEVs.